Switch From Premixed Human Insulin to Biphasic Insulin Aspart in the Netherlands

SWITCH Mixtard® 30 NovoLet® to NovoMix® 30 FlexPen®. An Observational Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01536626

Acronym

SWITCH

Enrollment

211

Registered

2012-02-22

Start date

2006-06-09

Completion date

2007-04-10

Last updated

2017-02-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This study is conducted in Europe. The aim of this observational study is to observe and investigate the process of switching from premixed human insulin 30/70 (BHI 30) to biphasic insulin aspart 30/70 (BIAsp 30) in an outpatient setting.

Interventions

DRUGbiphasic insulin aspart 30

Prescription at the discretion of the treating physician

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Type 2 diabetic subjects treated with BHI 30

Design outcomes

Primary

Measure	Time frame
HbA1c (glycosylated haemoglobin)	—

Secondary

Measure	Time frame
Treatment satisfaction: ITSQ (Insulin Treatment Satisfaction Questionnaire)	—
Quality of Life (QoL) using the World Health Organization Wellbeing Index (WHO-5)	—
Number of hypoglycaemic events	—

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026